Relay Therapeutics (RLAY) Operating Margin: 2020-2025
Historic Operating Margin for Relay Therapeutics (RLAY) over the last 3 years, with Jun 2025 value amounting to -11,351.11%.
- Relay Therapeutics' Operating Margin was N/A to -11,351.11% in Q2 2025 from the same period last year, while for Jun 2025 it was -1,868.34%, marking a year-over-year change of. This contributed to the annual value of -3,722.07% for FY2024, which is 226196.00% down from last year.
- Latest data reveals that Relay Therapeutics reported Operating Margin of -11,351.11% as of Q2 2025, which was down 927.06% from -1,105.21% recorded in Q1 2025.
- Relay Therapeutics' 5-year Operating Margin high stood at 9,219,600.00% for Q4 2023, and its period low was -89,117.65% during Q2 2023.
- For the 3-year period, Relay Therapeutics' Operating Margin averaged around 1,296,008.93%, with its median value being -1,105.21% (2025).
- As far as peak fluctuations go, Relay Therapeutics' Operating Margin slumped by 74,129,766bps in 2021, and later soared by 924,839,486bps in 2023.
- Relay Therapeutics' Operating Margin (Quarterly) stood at -11,944.09% in 2021, then slumped by 1,685,077bps to -28,794.86% in 2022, then soared by 924,839,486bps to 9,219,600.00% in 2023, then skyrocketed by 4,386,559bps to -903.00% in 2024, then crashed by 20,221bps to -11,351.11% in 2025.
- Its Operating Margin stands at -11,351.11% for Q2 2025, versus -1,105.21% for Q1 2025 and -903.00% for Q1 2024.